| Autor: |
Venegas Garrido C; Division of Respirology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada., Nair P; Division of Respirology, Department of Medicine, McMaster University, Hamilton, Ontario, Canada., Dávila I; Servicio de Alergia, Hospital Universitario de Salamanca, Salamanca, Spain.; Departamento de Ciencias Biomédicas y del Diagnóstico, Facultad de Medicina, Universidad de Salamanca, Salamanca, Spain.; Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), Red de Enfermedades Inflamatorias (REI), Instituto de Salud Carlos III, Madrid, Spain., Pérez de Llano L; Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, Spain.; Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina, Facultade de Medicina e Odontoloxia, Universidad de Santiago de Compostela, Santiago de Compostela, Spain. |
| Abstrakt: |
The airway epithelium is the first line of defense of the respiratory system against the external environment. It plays an active role in the initiation of immune and allergic responses against potential hazards. Among the various specialized cells and cytokines that participate in epithelium-induced responses, alarmins are particularly interesting, given their ample role in mediating T2 and non-T2 inflammatory mechanisms involved in the pathogenesis of asthma. Thymic stromal lymphopoietin (TSLP) is an alarmin with broad effects in asthma that result from its widespread action on multiple cell types, including eosinophils, mast cells, dendritic cells, and group-2 innate lymphoid cells. Its role in allergy-mediated responses, eosinophilic inflammation, airway hyperresponsiveness, mucus hyperproduction, viral tolerance, and airway remodeling is of the utmost importance, as more comprehensive asthma assessments have been developed to explore these pathogenic features. Therefore, blockade with targeting molecules, such as monoclonal antibodies, has emerged as a promising therapeutic option, particularly in patients with multiple pathogenic pathways. In this review, we examine the roles of alarmins (mainly TSLP) in the pathogenesis of asthma and clinical expression and discuss the effects of inhibiting TSLP on several inflammatory and clinical outcomes. We also review the literature supporting treatment with anti-TSLP biologics and the unanswered questions and unmet needs associated with targeting alarmins in asthma. |
